Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ONS

Oncobiologics (ONS) Stock Price, News & Analysis

Oncobiologics logo

About Oncobiologics Stock (NASDAQ:ONS)

Advanced Chart

Key Stats

Today's Range
$1.52
$1.62
50-Day Range
$0.72
$7.40
52-Week Range
$0.57
$1.53
Volume
229,103 shs
Average Volume
69,024 shs
Market Capitalization
$111.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Receive ONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

ONS Stock News Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Are Away Carry-Ons Worth the Hype?
ONS - the Office of National Statistics
See More Headlines

ONS Stock Analysis - Frequently Asked Questions

Oncobiologics (ONS) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR) and Exelixis (EXEL).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONS
Previous Symbol
NYSE:ONS
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,840,000.00
Net Margins
-464.47%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.81 million
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-1.14

Miscellaneous

Free Float
N/A
Market Cap
$111.91 million
Optionable
Not Optionable
Beta
-0.27
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ONS) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners